Kentuckiana Pain Specialists PSC
Kentuckiana Pain Specialists PSC was paid $1.04M by Medicaid between Jan 2018 and Nov 2024, across 22 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 20% of everything it billed.
LOUISVILLE, KY 40241
Next to other Durable Medical Equipment & Medical Supplies providers in Kentucky
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,348 | $238K | |
| 2019 | 4,892 | $247K | |
| 2020 | 4,335 | $97K | |
| 2021 | 6,658 | $124K | |
| 2022 | 3,974 | $116K | |
| 2023 | 3,340 | $173K | |
| 2024incomplete | 647 | $50K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 20% | 1,646 | 1,309 | $212K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 7,981 | 3,915 | $172K |
| S9328 | Home infusion therapy, implanted pump pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | 13% | 647 | 322 | $134K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.9% | 2,726 | 2,133 | $103K |
| 76942 | 9.0% | 3,575 | 2,241 | $94K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.2% | 3,277 | 2,153 | $86K |
| 62370 | 7.6% | 3,317 | 2,154 | $79K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 4.6% | 1,652 | 927 | $48K |
| 62323 | 3.0% | 474 | 276 | $31K | |
| A4220 | Refill kit for implantable infusion pump | 2.6% | 731 | 298 | $27K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.2% | 334 | 254 | $23K |
| 99601 | 1.6% | 944 | 408 | $17K |
10 more codes
| 62368 | 1.1% | 1,021 | $12K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 266 | $2K |
| 95909 | <1% | 20 | $2K | |
| 95943 | <1% | 30 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 16 | $925.31 |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 14 | $646.23 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $525.17 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 319 | $189.86 |
| 93040 | <1% | 17 | $104.90 | |
| A4550 | Surgical trays | 0% | 173 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.